References
- Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 1987; 83: 437–443
- Hayward C P, Sutton D M, Carter W H, Campbell E D, Scott J G, Francombe W H, Shumak K H, Baker M A. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome. Arch Intern Med 1994; 154: 982–987
- Bell W R, Braine H G, Ness P M, Kickler T S. Improved survival in thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome. N Engl J Med 1991; 325: 398–403
- Lian E C, Byrnes J J, Harkness D R. Two successful pregnancies in a woman with chronic thrombotic thrombocytopenic purpura treated by plasma infusion. Am J Hematol 1984; 16: 287–291
- Wurzel J M. TTP lesions in placenta but not fetus (letter). N Engl J Med 1979; 301: 503–504
- Asada Y, Sumiyoski A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985; 38: 469–479
- Ruggenenti P, Galbusera M, PlataCarnejo R, Bellavita P, Remuzzi G. Thrombotic thrombocytopenic purpura. Evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993; 21: 314–318
- Moake J L, Rudy C K, Troll J H, Weinstein M J, Colannino N M, Azocar J, Seder R H, Hong S L, Deykin D. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432–1435
- Forsyth K D, Simpson A C, Fitzpatrick M M, Barratt T M, Levinsky R J. Neutrophil‐medicated endothelial injury in hemolytic uremic syndrome. Lancet 1989; 2: 411–414
- Chignard M, Ballay V, Renesto P. Leucocyte elastase‐mediated release of von Willebrand factor from cultured endothelial cells. Eur Respir J 1993; 6: 791–796
- Galbusera M, Ruggenenti P, Noris M, Burnouf‐Radosevich M, Benigni A, Mannucci P M, Remuzzi G. Alpha‐1 antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet 1995; 345: 224–225
- Kelton J G, Warkentin T E, Hayward C P, Murphy W G, Moore J C. Calpain activity in patients with thrombotic thrombcytopenic purpura is associated with platelet microparticles. Blood 1992; 80: 2246–2251
- Moore J C, Murphy W G, Kelton J G. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Haematol 1990; 74: 457–464
- Schmaier A H, Bradford H, Silver L D, Farber A, Scott C F, Schutsky D, Colman R W. High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 1986; 77: 1565–1573
- Thompson C E, Damon L E, Ries C A, Linker C A. Thrombotic microangiopathies in the 1980′s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80(8)1890–1895
- Rock G A, Shumak K H, Buskard N A, Blanchette V S, Kelton J G, Nair R C, Spasoff R A. Canadian Apheresis Study Group: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393–397